Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.33 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.32 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.32 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12118613 | 0.90 | GLP1R (0.42) | GLP1RMEN1KMT2AFAAHPAOX | |
| SCHEMBL14683527 | 0.88 | GLP1R (0.44) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL14683467 | 0.88 | GLP1R (0.44) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL71906 | 0.88 | MEN1 (0.45) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL71147 | 0.88 | GLP1R (0.46) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL14683460 | 0.88 | GLP1R (0.41) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL71315 | 0.88 | GLP1R (0.46) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL13805652 | 0.86 | GLP1R (0.49) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL14683575 | 0.85 | FAAH (0.43) | GLP1RMEN1KMT2AFAAHTSHR | |
| SCHEMBL13805654 | 0.85 | GLP1R (0.53) | GLP1RMEN1KMT2AFAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633459-B2 | GIP derivatives and uses thereof | NOVO NORDISK A/S (DK) | 2023-04-25 | — | — | US | disclosed |
| US-20220000982-A1 | GIP DERIVATIVES AND USES THEREOF | NOVO NORDISK A/S (DK) | 2022-01-06 | — | — | US | disclosed |
| US-20110275559-A1 | Long-Acting Y2 and/or Y4 Receptor Agonists | NOVO NORDISK A/S (DK) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000982-A1 | GIP DERIVATIVES AND USES THEREOF | GIPR, GLP1R, GPR119 | GLP1R 2/4885MEN1 1878/4885KMT2A 4381/4885 |
| US-11633459-B2 | GIP derivatives and uses thereof | GIPR, GLP1R, GPR119 | GLP1R 2/4885MEN1 1878/4885KMT2A 4381/4885 |
| US-20110275559-A1 | Long-Acting Y2 and/or Y4 Receptor Agonists | NPY4R, NPY1R, NPY2R | GLP1R 6/4885MEN1 2452/4885KMT2A 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.